Gilead's HIV drug meets goal in four late-stage studies

Gilead Sciences Inc said a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes